H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44

Moomoo News03:36 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $44 Price Target

BenzingaNov 18 07:46 ET

Strategic Position and Acquisition Interest Bolster Buy Rating for Summit Therapeutics

TipRanksNov 18 06:25 ET · Ratings

BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up

Zacks Nov 14 10:05 ET

Merck to Buy Rights to Chinese Cancer Drug for up to $3.3B

Seeking AlphaNov 14 07:34 ET

PRIVACY ALERT: Summit Pathology Under Investigation for Data Breach of Over 1.8 Million Patient Records

PR NewswireNov 12 20:19 ET